Pay in 4 interest-free payments of $5.00 Learn more
Ships within 48 hours · Estimated delivery Aug 19 - Aug 24
Based on the clinical evidence and the patient profiles where the compound appears most applicable, the following characteristics tend to describe good candidates for AOD 9604 evaluation when it is medically supervised: Patients with stubborn localized fat deposits that have not responded to diet and exercise, particularly visceral and lower abdominal fat Patients who cannot tolerate GLP-1 medications due to nausea, gastrointestinal side effects, or contraindications Active patients with reasonable baseline metabolic health who want a targeted lipolytic tool to complement their training and nutrition program Patients already on a peptide protocol who want to add a fat-targeting element to a GHK-Cu, NAD+, or sermorelin stack Patients who are not candidates for stimulant-based fat loss medications due to cardiovascular sensitivity, anxiety, or blood pressure concerns AOD 9604 is not appropriate as a standalone weight loss strategy for patients with significant obesity, insulin resistance, or metabolic syndrome
It selectively decreases visceral fat and may improve cholesterol levels and insulin sensitivity in overweight females
In some cases, it can be injected subcutaneously (under the skin)
Do not inject directly into the tendon itself
The counterintuitive implication: the person who makes their training environment maximally stimulating every session will burn out faster than the person who deliberately introduces variability
Bac water produced or sourced specifically for peptide reconstitution with verifiable USP composition, intact chain of custody, and a vendor accountable for performance actually delivers the 28-day window
US$ 22.12
US$ 24.90
US$ 24.58
US$ 21.35
US$ 23.46
US$ 26.54
US$ 22.94
